These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 16278418)

  • 21. No-carrier-added iodine-131-MIBG: evaluation of a therapeutic preparation.
    Mairs RJ; Cunningham SH; Russell J; Armour A; Owens J; McKellar K; Gaze MN
    J Nucl Med; 1995 Jun; 36(6):1088-95. PubMed ID: 7769433
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: pharmacokinetic and pharmacodynamic evaluation.
    Guichard S; Montazeri A; Chatelut E; Hennebelle I; Bugat R; Canal P
    Clin Cancer Res; 2001 Oct; 7(10):3222-8. PubMed ID: 11595718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimizing MIBG therapy of neuroendocrine tumors: preclinical evidence of dose maximization and synergy.
    Mairs RJ; Boyd M
    Nucl Med Biol; 2008 Aug; 35 Suppl 1():S9-20. PubMed ID: 18707637
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparison of targeting of neuroblastoma with mIBG and anti L1-CAM antibody mAb chCE7: therapeutic efficacy in a neuroblastoma xenograft model and imaging of neuroblastoma patients.
    Hoefnagel CA; Rutgers M; Buitenhuis CK; Smets LA; de Kraker J; Meli M; Carrel F; Amstutz H; Schubiger PA; Novak-Hofer I
    Eur J Nucl Med; 2001 Mar; 28(3):359-68. PubMed ID: 11315605
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hyperbaric oxygen enhances the effects of meta-iodobenzylguanidine (MIBG) on energy metabolism and lipid peroxidation in the human neuroblastoma cell line SK-N-BE(2C).
    Cornelissen J; Van Kuilenburg AB; Elzinga L; Van der Kleij AD; Voûte PA; Van Gennip AH
    Anticancer Res; 1997; 17(1A):259-64. PubMed ID: 9066662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radiosensitization of noradrenaline transporter-expressing tumour cells by proteasome inhibitors and the role of reactive oxygen species.
    Rae C; Tesson M; Babich JW; Boyd M; Mairs RJ
    EJNMMI Res; 2013 Nov; 3(1):73. PubMed ID: 24219987
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Using pharmacokinetic and pharmacodynamic modeling and simulation to evaluate importance of schedule in topotecan therapy for pediatric neuroblastoma.
    Panetta JC; Schaiquevich P; Santana VM; Stewart CF
    Clin Cancer Res; 2008 Jan; 14(1):318-25. PubMed ID: 18172284
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytotoxic effects of m-[131I]- and m-[125I]iodobenzylguanidine on the human neuroblastoma cell lines SK-N-SH and SK-N-LO.
    Bruchelt G; Girgert R; Buck J; Wolburg H; Niethammer D; Treuner J
    Cancer Res; 1988 Jun; 48(11):2993-7. PubMed ID: 3365688
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma.
    Gaze MN; Chang YC; Flux GD; Mairs RJ; Saran FH; Meller ST
    Cancer Biother Radiopharm; 2005 Apr; 20(2):195-9. PubMed ID: 15869455
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determination of the optimal combination chemotherapy regimen for treatment of platinum-resistant ovarian cancer in nude mouse model.
    Saucier JM; Yu J; Gaikwad A; Coleman RL; Wolf JK; Smith JA
    J Oncol Pharm Pract; 2007 Mar; 13(1):39-45. PubMed ID: 17621566
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [(131)I] and [(125)I] metaiodobenzylguanidine therapy in macroscopic and microscopic tumors: a comparative study in SK-N-SH human neuroblastoma and PC12 rat pheochromocytoma xenografts.
    Rutgers M; Buitenhuis CK; van der Valk MA; Hoefnagel CA; Voûte PA; Smets LA
    Int J Cancer; 2000 Dec; 90(6):312-25. PubMed ID: 11180134
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of the norepinephrine transporter as a reporter gene for non-invasive imaging of genetically modified cells.
    Anton M; Wagner B; Haubner R; Bodenstein C; Essien BE; Bönisch H; Schwaiger M; Gansbacher B; Weber WA
    J Gene Med; 2004 Jan; 6(1):119-26. PubMed ID: 14716684
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood-brain barrier and survival of brain tumor-bearing animals.
    Du J; Lu WL; Ying X; Liu Y; Du P; Tian W; Men Y; Guo J; Zhang Y; Li RJ; Zhou J; Lou JN; Wang JC; Zhang X; Zhang Q
    Mol Pharm; 2009; 6(3):905-17. PubMed ID: 19344115
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with alpha-, beta-, and auger electron-emitting radionuclides.
    Boyd M; Ross SC; Dorrens J; Fullerton NE; Tan KW; Zalutsky MR; Mairs RJ
    J Nucl Med; 2006 Jun; 47(6):1007-15. PubMed ID: 16741311
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Celecoxib prevents neuroblastoma tumor development and potentiates the effect of chemotherapeutic drugs in vitro and in vivo.
    Ponthan F; Wickström M; Gleissman H; Fuskevåg OM; Segerström L; Sveinbjörnsson B; Redfern CP; Eksborg S; Kogner P; Johnsen JI
    Clin Cancer Res; 2007 Feb; 13(3):1036-44. PubMed ID: 17289900
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interferon beta-mediated vessel stabilization improves delivery and efficacy of systemically administered topotecan in a murine neuroblastoma model.
    Dickson PV; Hagedorn NL; Hamner JB; Fraga CH; Ng CY; Stewart CF; Davidoff AM
    J Pediatr Surg; 2007 Jan; 42(1):160-5; discussion 165. PubMed ID: 17208558
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is there a benefit of 131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004.
    Schmidt M; Simon T; Hero B; Eschner W; Dietlein M; Sudbrock F; Bongartz R; Berthold F; Schicha H
    Nuklearmedizin; 2006; 45(4):145-51; quiz N39-40. PubMed ID: 16964339
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.
    Tijink BM; Neri D; Leemans CR; Budde M; Dinkelborg LM; Stigter-van Walsum M; Zardi L; van Dongen GA
    J Nucl Med; 2006 Jul; 47(7):1127-35. PubMed ID: 16818947
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential response of tumor cells and normal fibroblasts to fractionated combined treatment with topotecan and ionizing radiation.
    Ohneseit PA; Wildemann A; Herskind C; Bamberg M; Rodemann HP
    Int J Radiat Biol; 2002 Feb; 78(2):125-32. PubMed ID: 11779362
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and evaluation of 4-[18F]fluoropropoxy-3-iodobenzylguanidine ([18F]FPOIBG): A novel 18F-labeled analogue of MIBG.
    Vaidyanathan G; McDougald D; Koumarianou E; Choi J; Hens M; Zalutsky MR
    Nucl Med Biol; 2015 Aug; 42(8):673-84. PubMed ID: 25956997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.